Biogen Idec Charts A New Course
Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri
You may also be interested in...
Capital Allocation In The Age Of Shareholder Activism
Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.
Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
Energized Biogen Idec On Track For Two Filings In 2012
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.